From: Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways
No. of PDX model
TGIs (%)
Ki-67 (%)
Gimatecan
Irinotecan
Control
1
110.1
75.4
–a
2
106.6
76.1
100
60
3
84.4
24.1
70
10
4
91.7
15.1
40
5
108.7
40.6
50